Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 40403 | 12.29 |
09:34 ET | 34969 | 12.22 |
09:36 ET | 35834 | 12.2534 |
09:38 ET | 30090 | 12.2899 |
09:39 ET | 74614 | 12.33 |
09:41 ET | 22029 | 12.28 |
09:43 ET | 20226 | 12.31 |
09:45 ET | 13582 | 12.32 |
09:48 ET | 21742 | 12.3924 |
09:50 ET | 32931 | 12.35 |
09:52 ET | 21926 | 12.28 |
09:54 ET | 30288 | 12.23 |
09:56 ET | 26402 | 12.31 |
09:57 ET | 31438 | 12.18 |
09:59 ET | 24827 | 12.23 |
10:01 ET | 27223 | 12.3 |
10:03 ET | 19721 | 12.26 |
10:06 ET | 15201 | 12.24 |
10:08 ET | 7344 | 12.28 |
10:10 ET | 21140 | 12.295 |
10:12 ET | 21201 | 12.3113 |
10:14 ET | 12869 | 12.27 |
10:15 ET | 13018 | 12.305 |
10:17 ET | 7217 | 12.27 |
10:19 ET | 4139 | 12.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 1.9B | -4.4x | --- |
PTC Therapeutics Inc | 2.9B | -5.9x | --- |
ACADIA Pharmaceuticals Inc | 2.6B | 87.0x | --- |
Azenta Inc | 2.4B | -17.7x | --- |
Guardant Health Inc | 2.8B | -5.6x | --- |
P3 Health Partners Inc | 136.6M | -0.7x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
---|---|
Revenue (TTM) | $987.7M |
Shares Outstanding | 160.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.03 |
EPS | $-2.76 |
Book Value | $-5.14 |
P/E Ratio | -4.4x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.